Literature DB >> 11722995

Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond.

K M Sullivan1, C A Dykewicz, D L Longworth, M Boeckh, L R Baden, R H Rubin, K A Sepkowitz.   

Abstract

This review presents evidence-based guidelines for the prevention of infection after blood and marrow transplantation. Recommendations apply to all myeloablative transplants regardless of recipient (adult or child), type (allogeneic or autologous) or source (peripheral blood, marrow or cord blood) of transplant. In Section I, Dr. Dykewicz describes the methods used to rate the strength and quality of published evidence supporting these recommendations and details the two dozen scholarly societies and federal agencies involved in the genesis and review of the guidelines. In Section II, Dr. Longworth presents recommendations for hospital infection control. Hand hygiene, room ventilation, health care worker and visitor policies are detailed along with guidelines for control of specific nosocomial and community-acquired pathogens. In Section III, Dr. Boeckh details effective practices to prevent viral diseases. Leukocyte-depleted blood is recommended for cytomegalovirus (CMV) seronegative allografts, while ganciclovir given as prophylaxis or preemptive therapy based on pp65 antigenemia or DNA assays is advised for individuals at risk for CMV. Guidelines for preventing varicella-zoster virus (VZV), herpes simplex virus (HSV) and community respiratory virus infections are also presented. In Section IV, Drs. Baden and Rubin review means to prevent invasive fungal infections. Hospital design and policy can reduce exposure to air contaminated with fungal spores and fluconazole prophylaxis at 400 mg/day reduces invasive yeast infection. In Section V, Dr. Sepkowitz details effective clinical practices to reduce or prevent bacterial or protozoal disease after transplantation. In Section VI, Dr. Sullivan reviews vaccine-preventable infections and guidelines for active and passive immunizations for stem cell transplant recipients, family members and health care workers.

Entities:  

Mesh:

Year:  2001        PMID: 11722995     DOI: 10.1182/asheducation-2001.1.392

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  29 in total

1.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.

Authors:  Richard A Nash; Peter A McSweeney; Leslie J Crofford; Muneer Abidi; Chien-Shing Chen; J David Godwin; Theodore A Gooley; Leona Holmberg; Gretchen Henstorf; C Fred LeMaistre; Maureen D Mayes; Kevin T McDonagh; Bernadette McLaughlin; Jerry A Molitor; J Lee Nelson; Howard Shulman; Rainer Storb; Federico Viganego; Mark H Wener; James R Seibold; Keith M Sullivan; Daniel E Furst
Journal:  Blood       Date:  2007-04-23       Impact factor: 22.113

Review 2.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

3.  [Therapy of herpes zoster].

Authors:  A J Ullmann
Journal:  Internist (Berl)       Date:  2008-07       Impact factor: 0.743

4.  Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology.

Authors:  Jessica E Morgan; Hadeel Hassan; Julia V Cockle; Christopher Lethaby; Beki James; Robert S Phillips
Journal:  Support Care Cancer       Date:  2016-09-11       Impact factor: 3.603

Review 5.  A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea.

Authors:  Sharon Elad; Yehuda Zadik; Ian Hewson; Allan Hovan; M Elvira P Correa; Richard Logan; Linda S Elting; Fred K L Spijkervet; Michael T Brennan
Journal:  Support Care Cancer       Date:  2010-06-11       Impact factor: 3.603

6.  The role of prophylactic antimicrobials during autologous stem cell transplantation: a single-center experience.

Authors:  B S Sohn; D H Yoon; S Kim; K Lee; E H Kang; J S Park; D H Lee; S H Kim; J Huh; C Suh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-04       Impact factor: 3.267

Review 7.  Principles and overview of allogeneic hematopoietic stem cell transplantation.

Authors:  Sergio Giralt; Michael R Bishop
Journal:  Cancer Treat Res       Date:  2009

8.  Antimicrobial chlorhexidine/silver sulfadiazine-coated central venous catheters versus those uncoated in patients undergoing allogeneic stem cell transplantation.

Authors:  Samuel Vokurka; Klara Kabatova-Maxova; Jana Skardova; Eva Bystricka
Journal:  Support Care Cancer       Date:  2008-05-01       Impact factor: 3.603

Review 9.  The central nervous system complications of bone marrow transplantation in children.

Authors:  Shoko Yoshida; Katsumi Hayakawa; Akira Yamamoto; Hiroshi Kuroda; Shinsaku Imashuku
Journal:  Eur Radiol       Date:  2008-05-20       Impact factor: 5.315

10.  Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties.

Authors:  O Penack; G Tridello; J Hoek; G Socié; D Blaise; J Passweg; P Chevallier; C Craddock; N Milpied; H Veelken; J Maertens; P Ljungman; J Cornelissen; A Thiebaut-Bertrand; B Lioure; M Michallet; S Iacobelli; A Nagler; M Mohty; S Cesaro
Journal:  Bone Marrow Transplant       Date:  2015-10-26       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.